While the therapies using Bcr-Abl tyrosine kinase inhibitors achieve deep remissions and long-term survival for CML patients, overall survival of the patients with p185Bcr-Abl-positive ALL is still low and drug resistance is more frequently observed [6–8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.